Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report

0Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND: Ameloblastomas are uncommon locally aggressive tumors of odontogenic epithelium that rarely metastasize. Currently, there is no standard of care for the metastatic forms. Several studies have shown that ameloblastomas frequently have a BRAF mutation. CASE PRESENTATION: We report a case of a 33-year-old Caucasian woman with ameloblastoma diagnosed 30 years ago who developed lung metastasis 19 years ago. Systemic oral treatment with vemurafenib, a BRAF inhibitor, was initiated 28 months ago within the AcSé French basket clinical trial of vemurafenib. CONCLUSIONS: The patient has shown a durable clinical, functional, and radiographic partial response with vemurafenib. These observations suggest the possibility of introducing neoadjuvant and/or adjuvant targeted therapy in locally advanced ameloblastoma to improve outcome. BRAF inhibition has proved to be an efficient strategy in patients with a BRAF-mutated ameloblastoma.

Cite

CITATION STYLE

APA

Broudic-Guibert, M., Blay, J. Y., Vazquez, L., Evrard, A., Karanian, M., Taïeb, S., … Arnaud, A. (2019). Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report. Journal of Medical Case Reports, 13(1), 245. https://doi.org/10.1186/s13256-019-2140-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free